Probiotics, prebiotics and postbiotics show promise as add-ons for acne, but proof of superiority is lacking
A systematic review of 33 studies (2,112 patients) finds gut-microbiome therapies safe and linked to acne lesion reductions, though not clearly better than controls.
Résumé
This systematic review pooled 33 clinical studies with 2,112 people with mostly mild-to-moderate acne who used oral or topical prebiotics, probiotics, or postbiotics for 4–25 weeks. No serious adverse events were reported. Average total lesion reductions were about 37% for prebiotics, 45% for probiotics, and 50% for postbiotics. Control groups improved by about 37%, mostly because the biotics were added to standard treatments such as antibiotics or retinoids. Each biotic type improved significantly from baseline, but none was statistically better than controls, and the routes of administration did not differ. Probiotics have the largest evidence base. Prebiotics and postbiotics look like plausible adjuncts. The authors call for larger, standardized, head-to-head trials with longer follow-up.
Résumé détaillé
Acne vulgaris affects roughly 85% of adolescents and young adults, and standard treatments such as antibiotics and isotretinoin can cause side effects or drive resistance. Emerging data link acne to gut and skin dysbiosis, including reduced gut diversity and fewer Lactobacillus and Bifidobacterium. That has made microbiome-modulating products an attractive complementary option. This review asks whether prebiotics (substrates that feed beneficial microbes), probiotics (live microbes), and postbiotics (inactivated microbes or their products) are safe and effective for acne.
The authors ran a PRISMA-guided search of PubMed, Embase, Web of Science, and Cochrane through August 2025. From 2,435 records they included 33 randomized, cohort, and split-face studies across 14 countries, covering 2,112 participants (mean age about 25). Five studies tested prebiotics, 24 probiotics, and 7 postbiotics, with a few comparing categories. Oral products dominated the prebiotic and probiotic studies, and topical products dominated the postbiotic ones. Three reviewers screened and extracted data. Bias was assessed with Cochrane RoB 1.0 by a single reviewer. The authors pooled percent lesion reductions with t-tests and ANOVA.
No serious adverse events were reported. Side effects were mild, such as transient bloating or gut discomfort with oral products and dryness or flushing with topical ones. Pooled mean total lesion reductions were −37.2% for prebiotics, −45.2% for probiotics, and −49.5% for postbiotics, versus −37% in control arms. Each biotic category improved significantly from baseline (prebiotics p=0.041, probiotics p<0.0001, postbiotics p=0.0089). Comparisons against controls, between categories, and between oral and topical routes were not significant. Individual trials suggested added value in combination: probiotics with doxycycline or isotretinoin improved lesion counts and eased side effects such as dryness and gastrointestinal upset, and a prebiotic FOS/GOS regimen modestly outperformed topical therapy alone (−34% vs −28%).
Clinically, probiotics have the most evidence and can reasonably be considered as add-ons to conventional therapy, or as an option for patients who prefer complementary approaches. Prebiotics may suit adjunctive or maintenance roles, particularly with suspected gut dysbiosis. Postbiotics showed the largest point estimate but are best seen as adjuncts for now. Proposed mechanisms include reduced C. acnes biofilm and lipase activity, lower inflammation, better barrier hydration, improved insulin sensitivity, and lower androgen signaling.
The main caveat is that the control arms improved almost as much as the biotic arms, because most studies tested add-on benefit. The lack of significant superiority therefore means the benefit attributable to the biotics themselves is unproven. Studies were small and short, products and strains were heterogeneous, and several were open-label. Larger, strain-standardized, head-to-head trials with long follow-up are needed.
Principales conclusions
- 33 studies (2,112 patients) found prebiotics, probiotics, and postbiotics safe, with no serious adverse events reported.
- Pooled total lesion reductions were −37.2% (prebiotics), −45.2% (probiotics), −49.5% (postbiotics) versus −37% in controls.
- Each biotic type improved significantly from baseline, but none differed significantly from controls or from the others.
- Probiotics added to doxycycline or isotretinoin improved lesion outcomes and eased side effects such as dryness and GI upset.
- Probiotics have the strongest evidence; prebiotics and postbiotics are promising adjuncts needing larger standardized trials.
Méthodologie
PRISMA-guided systematic review of RCTs, cohort, and case–control studies (search through August 2025; 2,435 records screened, 33 included). Three reviewers screened and extracted data, while a single reviewer assessed risk of bias with Cochrane RoB 1.0. Percent lesion reductions were pooled with one- and two-sample t-tests and ANOVA/Tukey tests, not a formal weighted meta-analysis.
Limites de l'étude
Control arms improved by about 37% because most trials added biotics to standard care, and no category beat controls significantly, so the independent effect of the biotics is uncertain. Studies were small, short, heterogeneous in strains and formulations, and often open-label or split-face, with risk of bias judged by one reviewer. Some table data and category labels are inconsistent (e.g., non-probiotic agents classed as probiotics, discordant lesion figures between text and table), which weakens the pooled estimates.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :